Cell (In Press)Original article
Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer
5-HT2AR agonist (non-brain-penetrant)Positive
AI Analysis
Summary
A non-brain-penetrant 5-HT2AR agonist selectively targeting peripheral receptors enhances antitumor CD8+ T cell immunity and improves immunotherapy responses in preclinical colorectal cancer models without inducing psychedelic effects.
Clinical Trial Data
Phase
Preclinical
Importance:3/10
Sentiment:
0.60
PreclinicalImmunotherapyColorectal cancer5-HT2ARCD8+ T cell immunityMechanism of action
Related Companies
Read the original article
Published by Cell (In Press) on August 4, 2026 12:00 AM